News | February 25, 2015

Optimal Tissue Debulking Protocol Defined for Treating In-Stent Restenosis

Testing performed with Boston Scientific’s Jetstream Navitus Atherectomy Device

Boston Scientific, Jetstream, CBSET, atherectomy, PAD

February 25, 2015 — CBSET, a not-for-profit preclinical research institute, announced that its scientists have defined the optimal tissue debulking protocol for treating in-stent restenosis (ISR) with Boston Scientific’s Jetstream Navitus atherectomy device. These findings were disclosed at the Cardiovascular Research Technologies 2015 annual scientific meeting (CRT 2015) in Washington, D.C.

The study (“Optimal Number of Runs Using the Jetstream Navitus Device to Achieve Maximum Tissue Debulking of In-Stent Restenosis in a Porcine Stent/Balloon Injury Overstretch Model”) determined that the Boston Scientific device achieved optimal tissue debulking after two blade-up (BU) runs, with no further gain in debulking after the second run. This study also confirmed that stent damage was minimal after the procedure, with no disruption to stent struts or stent integrity. Prior to this study, the number of runs needed to achieve optimal tissue debulking in ISR using the Jetstream Navitus device was unknown.

“Now we may proceed to translate these findings into clinical data, with the goal that optimal tissue removal or debulking will translate into (1) better patient outcomes, and (2) ideal coupling with adjunctive therapies such as drug-coated balloons. We believe that the optimal debulking process will give physicians the best acute procedural results and hopefully better long-term outcomes,” concluded the study’s principal investigator, Nicolas W. Shammas, M.D., president and research director, Midwest Cardiovascular Research Foundation.

The results of two related studies also were disclosed at CRT 2015:

  • “Minimal Plaque Surface Area and Minimal Luminal Area Needed for Effective Atherectomy using the JetStream Navitus in Treating In-Stent Restenosis of Femoral Artery in a Porcine Model”
  • “Intravascular Ultrasound Assessment of the Optimal Number of Runs Using the JetStream Navitus Device to Achieve Maximum Tissue Debulking in Femoral Artery in-Stent Restenosis Porcine Model”

 

For more information: www.cbset.org

Related Content

Lithotripsy Safe and Effective in Calcified Stenotic Peripheral Arteries
News | Peripheral Artery Disease (PAD) | December 04, 2018
New results from the DISRUPT PAD II study showed no perforations, embolization, reflow or abrupt closures with the...
Lutonix 014 Drug-Coated Balloon Safe and Effective Below the Knee
News | Peripheral Artery Disease (PAD) | November 07, 2018
The Lutonix Drug-Coated Balloon (DCB) showed statistically significant safety equivalence with a standard percutaneous...
Lokai Medical to Distribute NuCryo Vascular PolarCath Balloon Dilatation System in U.S.
News | Peripheral Artery Disease (PAD) | August 14, 2018
NuCryo Vascular announced that the company has signed a commercialization agreement with Lokai Medical, a specialty...
PQ Bypass Effective in Treating Extremely Long SFA Lesions at 12 Months
News | Peripheral Artery Disease (PAD) | July 02, 2018
The PQ Bypass Detour System showed promising 12-month durability for patients with extremely long blockages in the...
SCAI Releases Consensus Guidelines for Femoral-Popliteal Arterial Interventional Device Selection
News | Peripheral Artery Disease (PAD) | May 15, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) has released new guidelines to address the...
SCAI Launches Diagnosis and Treatment Toolkit for Peripheral Artery Disease
News | Peripheral Artery Disease (PAD) | May 14, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) announced the launch of the SCAI PAD Diagnosis and...
Critical Limb Ischemia Treatment Shows No Improvement at Three Months
News | Peripheral Artery Disease (PAD) | March 23, 2018
Patients with foot ulcers or gangrene who received the experimental drug JVS-100 did not show evidence of faster wound...
FDA Clears Corindus CorPath GRX for Peripheral Vascular Interventions
Technology | Peripheral Artery Disease (PAD) | February 20, 2018
Corindus Vascular Robotics Inc. announced today that it received 510(k) clearance from the U.S. Food and Drug...
News | Peripheral Artery Disease (PAD) | December 29, 2017
December 29, 2017 — iVascular announced the release of the new Oceanus 14 Pro percutaneous transluminal angioplasty (
Overlay Init